Clinical Trial Update: Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating a CD19/CD20 dual-targeted cell therapy for relapsed or refractory B-cell non-Hodgkin lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• CD19/CD20 dual-targeted cell therapy

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: B-Cell Non-Hodgkin Lymphoma-Recurrent, B-Cell Non-Hodgkin Lymphoma-Refractory | Phase 1 | Status: RECRUITING